ArticleScientific reports2025
C-reactive protein-triglyceride glucose index and heart failure in US adults from NHANES 2001-2010.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Association between C-reactive protein-triglyceride glucose index (CTI) and cardiovascular and all-cause mortality risk among the elderly population: insights from three datasets.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Remnant cholesterol inflammation index may be a superior biomarker to C-reactive protein-triglyceride glucose index in predicting carotid atherosclerosis risk.BMC endocrine disorders · 2026Article
- C-reactive protein-triglyceride glucose index as a predictor of heart failure risk in adults with MASLD: a prospective cohort study.Scientific reports · 2026Article
- Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study.Cardiovascular diabetology · 2026Article
- The Role of the C-Reactive Protein-Triglyceride Glucose Index in Predicting New-Onset Chronic Diseases: Evidence From a Longitudinal Cohort Study.Brain and behavior · 2026Article
- Prognostic value of the CRP-TyG index for in-hospital and 1-year mortality in patients with decompensated heart failure.BMC cardiovascular disorders · 2026Article
- TyG-HDL Outperforms TyG Combined With Obesity Indicators in Predicting Chronic Kidney Disease Associated With High Fasting Blood Glucose Levels in the Chinese Elderly Population: A Two-Stage Study Based on GBD 2023 and CHARLS Data.International journal of endocrinology · 2026Article
- Association between C-reactive protein to triglyceride-glucose index and atrial fibrillation: a cross-sectional analysis.Frontiers in endocrinology · 2026Article
- Article
- C-Reactive Protein-Triglyceride Glucose Index and Mortality in Patients with Ventricular Septal Rupture After Acute Myocardial Infarction.Journal of inflammation research · 2026Article
- Clinical Significance of the C-Reactive Protein-Triglyceride-Glucose Index in Cardiovascular Disease, Stroke, Cardiovascular-Kidney-Metabolic Syndrome, Cancer, Diabetes, and Osteoporosis: A Narrative Review.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The C-reactive protein(CRP)-triglyceride glucose index (CTI) is a new composite biomarker used to assess inflammation and insulin resistance(IR) severity. Heart failure (HF) poses a substantial epidemiological threat with increasing incidence and mortality worldwide. However, the relationship between CTI and HF has not been extensively investigated. Using cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) 2001-2010, 21,974 participants ≥ 20 years were included. HF diagnosis was based on self-reported medical history. Multivariable logistic regression adjusted for demographic, lifestyle, and clinical covariates. Smooth curve fitting analyzed dose-response relationships, while subgroup analyses explored effect heterogeneity. The research cohort comprised 21,974 individuals (631 HF cases, 21,343 non-HF). HF patients exhibited significantly higher CTI levels (p < 0.001), and a positive correlation with HF prevalence was observed (p < 0.001). Consistent positive associations were maintained across subgroups, with no significant interactions detected. Logistic regression analysis demonstrated adjusted ORs for HF per 1-unit CTI increase of 1.492 (model 1, unadjusted) and 1.279 (model 3, fully adjusted). Quartile analysis revealed a progressive increase in prevalent HF with higher CTI levels, and model 3 confirmed a nonlinear dose-response relationship (p < 0.001) with a threshold at 11.657. CTI is positively associated with the presence of HF in US adults, suggesting its potential as a biomarker for HF prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.